Article

Avastin for Refractory Glioblastoma and Oxaliplatin for Colon Cancer

As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at the ASCO meeting, adding oxaliplatin (Eloxatin) to a standard chemotherapy regimen for stage II or III colon cancer may provide a small five-year survival advantage.

Related Videos
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Christopher Bunick, MD, PhD: Facts About Systemic Therapies’ Safety, Mechanism of Action
Carla Nester, MD | Credit: HCPLive
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Related Content
Katherine R. Tuttle, MD, Clinical Professor of Medicine, University of Washington Medicine, and Executive Director for Research, Providence Health Care, and Regional Co-Principal Investigator, Institute of Translational Health Sciences, Providence Medical Research Center
October 26th 2024

Semaglutide Shows Benefit in CKD and Type 2 Diabetes Across Kidney Disease Severities

Victoria Johnson
Impact of CSU on Patient Quality of Life
October 25th 2024

Impact of CSU on Patient Quality of Life

David Khan, MD Kristin Sokol, MD Vivian Hernandez-Trujillo, MD Priya Bansal, MD
Despite Guidelines, Systemic Corticosteroids Remain Widely Prescribed for Atopic Dermatitis
October 26th 2024

Despite Guidelines, Systemic Corticosteroids Remain Widely Prescribed for Atopic Dermatitis

Tim Smith
Overview of CSU: Prevalence and Presentations
October 25th 2024

Overview of CSU: Prevalence and Presentations

David Khan, MD Kristin Sokol, MD Vivian Hernandez-Trujillo, MD Priya Bansal, MD
F. Perry Wilson, MD | Credit: Yale Medicine
October 25th 2024

KAT-AKI: Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients

Patrick Campbell
Hiddo Heerspink, PharmD, PhD | Credit: George Institute for Global Health
October 25th 2024

Semaglutide Shows Promise, Reduces UACR in Nondiabetic Kidney Disease

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.